DBPR728
DBPR728 is an acyl prodrug of 6K465 that carries fewer hydrogen bond donors. 6K465 acts as an Aurora kinase inhibitor that destabilizes MYC family cancer proteins and has antitumor efficacy. DBPR728 has the potential to inhibit cancers that overexpress C-MYC and N-MYC, with a 10-fold increase in oral bioavailability compared to 6K465[1].
Product Specifications
CAS Number
2702965-64-6
UNSPSC
12352005
Target
Aurora Kinase
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dbpr728.html
Purity
98.11
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N1CCC(NC2=NC(N3CCN(CC)CC3)=CC(NC4=CC(C)=NN4C(CC)=O)=N2)CC1)C5=CC=CC(Cl)=C5F
Molecular Formula
C29H37ClFN9O2
Molecular Weight
598.11
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
TNFS15 / VEGI (Vascular Endothelial Growth Inhibitor) (VEGI/2052R), CF647 conjugate, 0.1mg/mL
